Skip to main content
SpringerLink
Log in

Acitretin

A Review of its Pharmacology and Therapeutic Use

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Synopsis

Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects.

When used alone at a maintenance dosage of 30 to 50mg daily, acitretin is effective in the treatment of psoriasis, causing a reduction in the severity of scaling, erythema and induration. Efficacy appears to be further enhanced by combination with psoralen-ultraviolet A photochemotherapy (PUVA) or ultraviolet B irradiation (UVB). These combinations reduce the time to lesion clearance and reduce the total radiation dose, improving overall safety. Comparative studies have confirmed the equivalence of acitretin and etretinate with regard to efficacy and toxicity. Adverse reactions are dose-related and generally typical of hypervitaminosis A. Alopecia and mucocutaneous symptoms such as cheilitis and drying of the mucous membranes are particularly prevalent. Hypertriglyceridaemia and elevation of cholesterol levels also occur.

Examination of the pharmacokinetic profile of acitretin reveals its main advantage over etretinate. Acitretin is less lipophilic than etretinate, and its lack of sequestration into ‘deep’ fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate. Due to its teratogenic potential, acitretin is strictly contraindicated in women of childbearing potential unless effective contraceptive measures are employed. Etretinate has been identified in plasma samples of some patients treated with acitretin.

Thus, acetretin has an established place in the treatment of keratinising disorders, although its use in women of child-bearing potential must be accompanied by effective contraceptive measures, with a further 2-year contraceptive period after therapy completion.

Pharmacodynamic Properties

Investigation of the pharmacodynamic properties of acitretin has been restricted to some extent by the lack of a suitable experimental model. While in vitro results using normal human skin fibroblasts have been conflicting, acitretin generally modulates cell proliferation in cultures from hyperproliferative conditions such as psoriasis or neoplasia, and inhibits epidermal cell growth and differentiation. Acitretin also inhibits chemically induced hyperplasia, and causes regression or inhibits further growth and development of a number of established or transplantable carcinoma cell lines.

The mechanism of action of acitretin in hyperproliferative disorders has yet to be fully elucidated; however, there appear to be a number of cellular effects. Target receptor site candidates include the cellular retinoic acid binding protein (CRABP), the epidermal growth factor (EGF) receptor, and retinoic acid nuclear receptors (RARs). Acitretin binds competitively to CRABP, a protein present in high concentrations in psoriatic plaques, and induces a marked elevation of CRABP levels in normal epidermis. However, 13-cis-acitretin does not bind to CRABP and acitretin may act via activation of RARs following conversion to a substance which binds to these receptors. In addition, the EGF receptor may be involved since acitretin has been found to influence its normal modulation of cell growth in both normal fibroblasts and squamous carcinoma cell lines. Cyclic adenosine monophosphate (cAMP)-dependent protein kinases and ornithine decarboxylase are probable mediators of the clinical response.

In addition, acitretin demonstrates immunomodulatory and anti-inflammatory effects. It is hypothesised that the mechanisms entail inhibition of polymorphonuclear leucocyte accumulation in the stratum corneum, inhibition of lymphocytic blastogenesis by mitogens and stimulation of T cell-mediated cytotoxicity.

Pharmacokinetic Studies

Following oral administration of the drug to patients with psoriasis, peak plasma acitretin concentrations range from 98 to 526 µg/L and are reached approximately 1.9 hours after a single 40mg dose. Acitretin is widely distributed in the body and systemic bioavailability is approximately 60%. It is extensively bound to albumin and has a high affinity for CRABP. Less than 5% of acitretin is bound to lipoproteins and this is reflected in its comparative lack of sequestration into fatty ‘deep’ storage sites and its short terminal elimination half-life relative to etretinate. Multiple dose studies have indicated an elimination half-life of 50 to 60 hours, and neither acitretin nor its isomeric counterpart, 13-cis-acitretin, is detectable in plasma 3 to 4 weeks after cessation of long term therapy.

Isomeric interconversion is prevalent following oral administration of acitretin: mean maximum plasma concentrations of the 13-cis-isomeric metabolite are lower and occur slightly later than with acitretin. Plasma trough concentrations of this metabolite following long term administration of acitretin are about 5 times higher than those of the parent drug and the terminal elimination half-life is about 15 times longer. Acitretin is excreted predominantly via the renal and hepatic routes, as glucuronides in bile or as products with shortened side chains in urine. In blood, 13-cis-acitretin and 3 other metabolites have been identified.

Liquid chromatography/mass spectroscopy has identified etretinate in plasma samples of some patients treated with acitretin. The results obtained so far are of concern with regard to a potential teratogenic effect in female patients. Therefore, an increase in the post therapy contraception period to 2 years instead of the 2 months previously advocated is appropriate until clarification of these recent results have been obtained.

Therapeutic Efficacy

Trials with an initial double-blind phase and a subsequent noncomparative phase of up to 6 months duration have demonstrated the efficacy of orally administered acitretin (generally 25 to 75 mg/day) in the treatment of severe psoriasis. Variants of psoriasis vulgaris are notably susceptible to treatment and acitretin also appears to be effective against severe forms of pustular and erythrodermic psoriasis.

Preliminary studies in small patient populations and a number of individual case reports suggest that acitretin, 30 to 50 mg/day, is beneficial in a variety of other cutaneous disorders including Darier’s disease, lupus erythematosus and severe recessive x-linked ichthyosis. The rarity of these conditions prevents adequate extensive trials.

Double-blinding in placebo-controlled trials is difficult to maintain due to the ubiquitous and distinctive nature of acitretin-induced adverse effects. However, double-blinding strategies have been used effectively in studies in which a dose-finding phase preceded a longer term noncomparative phase.

Subjective assessments have revealed good to excellent (⩾ 50%) clearance of severe psoriasis in > 75% of patients: the severity of scaling, erythema and epidermal induration, and the percentage of body surface involvement, are reduced. Comparative studies in patients with psoriasis indicate that acitretin is comparable with etretinate in terms of therapeutic efficacy and adverse effects. When acitretin is combined with psoralen-ultraviolet A photochemotherapy (PUVA), clinical efficacy is improved, as evidenced by a higher complete remission rate and a reduced time to clearance of psoriasis. Total irradiation requirement is also reduced. Similar results are also achieved when acitretin is combined with ultraviolet B irradiation.

Adverse Effects

Acitretin therapy has distinctive adverse effects generally typical of hypervitaminosis A. While the incidence of mucocutaneous clinical adverse effects is high, their severity does not usually necessitate withdrawal of therapy, and they are completely reversed on cessation of treatment. Adverse effects are usually dose-related, although alopecia is also dependent on the duration of therapy. Mucocutaneous reactions are most common — drying of mucous membranes of the eyes, nose and lips, and cheilitis occurs in nearly all patients. Other clinical symptoms include alopecia, desquamation of the skin, pruritus and ‘sticky’ skin. Changes in the lipid profile are often observed. Hypertriglyceridaemia occurs in 35% of patients treated with acitretin 50 mg/day, but increases in serum cholesterol are less frequently reported. Liver enzyme levels are also adversely affected, hepatitis has been reported and acitretin therapy may have an adverse effect on bone. As with etretinate, acitretin is a potent teratogen.

Dosage and Administration

Initial acitretin dosage has usually ranged from 10 to 75 mg/day orally. After a few weeks, the dose should be individually adjusted to obtain optimum therapeutic response with tolerable adverse effects. Maintenance doses in such trials have ranged from 30 to 50 mg/day. Some authorities advocate low-dose therapy initially followed by a progressive dosage increase. Because of its potent teratogenicity and the detection of etretinate in patients treated with acitretin, the drug is contraindicated in women of childbearing potential unless effective contraceptive measures are adopted. It is essential that pregnancy be avoided for a full 2 years after therapy finishes, instead of the 2 months previously advocated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Apfel C, Crettaz M, Siegentaler G, Hunziker W. Synthetic retinoids: binding to retinoic acid receptors. In Saurat J-H (Ed.) Retinoids 10 years on, Korgen, Basel, 1991

    Google Scholar 

  • Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB. Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. Journal of the American Academy of Dermatology 19: 76–82, 1988

    PubMed  CAS  Google Scholar 

  • Bauer R, Orfanos CE. Trimethylmethoxyphenyl-retinoic acid (Ro 10-1670) inhibits mitogen-induced DNA-synthesis in peripheral blood lymphocytes in vitro. British Journal of Dermatology 105: 19–24, 1981a

    PubMed  CAS  Google Scholar 

  • Bauer R, Orfanos CE. Influence of retinoid on human blood cells in vitro. TMMP-retinoid inhibits the mitogenic properties of lectins and modulates the lymphocytic response. In C.E. Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 153–160, Springer-Verlag, 1981b

    Google Scholar 

  • Bauer R, Orfanos CE. Effects of synthetic retinoids on human peripheral blood lymphocytes and polymorphonuclears in vitro. In W.J. Cunliffe (Ed.) Retinoid therapy: a review of clinical and laboratory research, pp. 101–118, MTP Press Ltd, Boston, 1984

    Google Scholar 

  • Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature 333: 669–672, 1988

    PubMed  CAS  Google Scholar 

  • Berbis P, Bun H, Al Mallah NR, Durand A, Rognin C, et al. Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration. Dermatologica 177: 244–246, 1988a

    PubMed  CAS  Google Scholar 

  • Berbis Ph, Bun H, Geiger JM, Rognin C, Durand A, et al. Acitretin (RO 10-1670) and oral contraceptives: interaction study. Archives of Dermatological Research 280: 388–389, 1988b

    PubMed  CAS  Google Scholar 

  • Berbis Ph, Bun H, Durand A, Brindley C, Geiger JM, et al. Pharmacokinetic study of acitretin (Ro 10-1670) and its 13-cis metabolite after chronic administration. Journal of Investigative Dermatology 92: 136, 1989a

    Google Scholar 

  • Berbis P, Geiger J-M, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 178: 88–92, 1989b

    PubMed  CAS  Google Scholar 

  • Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger J-M, Puissant A, et al. Acetretin in the treatment of severe disorders of keratinization. Journal of the American Academy of Dermatology 24: 982–986, 1991

    PubMed  CAS  Google Scholar 

  • Boer J, Hermans J, Schothorst AA, Suurmond D. Comparison of phototherapy (UV-B) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis. Archives of Dermatology 120: 52–57, 1984

    PubMed  CAS  Google Scholar 

  • Bollag W. New retinoids with potential use in humans. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva, 1984, pp. 274–288, Karger, Basel, 1985

    Google Scholar 

  • Bouclier M, Shroot B, Eustache J, Hensby CN. A rapid and simple test system for the evaluation of the inhibitory activity of retinoids on induced ornithine decarboxylase activity in the hairless rat epidermis. Journal of Pharmacological Methods 16: 151–160, 1986

    PubMed  CAS  Google Scholar 

  • Brindley CJ. Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin). Dermatologica 178: 79–87, 1989

    PubMed  CAS  Google Scholar 

  • Brion DE, Raynaud F, Plet A, Laurent P, Leduc B. Effect of retinoids on cAMP-mediated events in human psoriatic fibroblasts. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva 1984, pp. 189–193, Karger, Basel, 1985

    Google Scholar 

  • Bruckner-Tuderman L, Sigg C, Geiger J-M, Gilardi S. Acitretin in the symptomatic therapy for severe recessive X-linked ichthyosis. Archives of Dermatology 124: 529–532, 1988

    PubMed  CAS  Google Scholar 

  • Byus CV, Klimpel GR, Lucas DO, Russell DH. Type I and type II cyclic AMP-dependent protein kinase as opposite effectors of lymphocyte mitogenesis. Nature 268: 63–64, 1977

    PubMed  CAS  Google Scholar 

  • Camenzind M, Geiger JM, Saurat JH. Clinical efficacy of Ro 10-1670, the main metabolite of Tigason®. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva 1984, pp. 305–308, Karger, Basel, 1985

    Google Scholar 

  • Chen DT. Human pregnancy experience with the retinoids. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva 1984, pp. 398–406, Karger, Basel, 1985

    Google Scholar 

  • Chopra DP, Wilkoff LJ. Reversal by Vitamin A analogues (retinoids) of hyperplasia induced by N-methyl-N’-nitro-N-nitrosoguanidine in mouse prostate organ cultures. Journal of the National Cancer Institute 58: 923–930, 1977

    PubMed  CAS  Google Scholar 

  • Chopra DP, Wilkoff LJ. Effect of retinoids and estrogens on testosterone-induced hyperplasia of mouse prostate expiants in organ culture (40654). Proceedings of the Society for Experimental Biology and Medicine 162: 229–234, 1979

    PubMed  CAS  Google Scholar 

  • Claudy AL, de Bouteiller O, Touraine JL. Trimethylmethoxyphenyl-retinoic acid (Ro 10-1670) and lymphocyte DNA synthesis activity in vitro. Dermatologica 169: 18–22, 1984

    PubMed  CAS  Google Scholar 

  • Cormane RH. Immunopathology of psoriasis. Archives of Dermatological Research 270: 201–213, 1981

    PubMed  CAS  Google Scholar 

  • Costa M, Gerner EW, Russell DH. Cyclic AMP levels and type I and II cyclic AMP-dependent protein kinase activity in synchronized cells and in quiescent cultures stimulated to proliferate. Biochimica et Biophysica Acta 538: 1–10, 1978

    PubMed  CAS  Google Scholar 

  • Creech-Kraft J, Sparenberg Th, Loefberg B, Reiners J, Kochhar DM, et al. Teratogenicity and transplacental pharmacokinetics of etretinate, etretin and motretinid in the mouse: comparison to in vitro activities. Abstract. Teratology 34: 412–413, 1986

    Google Scholar 

  • Dickson IR. Influence of retinoids on bone formation in vitro. Calcified Tissue International 39 (Suppl.): 28, 1986

    Google Scholar 

  • DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. New England Journal of Medicine 315: 1177–1182, 1986

    PubMed  CAS  Google Scholar 

  • Dubertret L. Etretinate in psoriasis: advantages of low doses progressively increased. Journal of the American Academy of Dermatology 13: 831, 1985

    Google Scholar 

  • Dubertret L, Lebreton C, Touraine R. Inhibition of neutrophil migration by etretinate and its main metabolite. British Journal of Dermatology 107: 681–685, 1982a

    PubMed  CAS  Google Scholar 

  • Dubertret L, Lebreton C, Touraine R. Neutrophil studies in psoriatics: in vivo migration, phagocytosis and bacterial killing. Journal of Investigative Dermatology 79: 74–78, 1982b

    PubMed  CAS  Google Scholar 

  • Dupuy P, Bagot M, Heslan M, Dubertret L. Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. Journal of Investigative Dermatology 93: 455–459, 1989

    PubMed  CAS  Google Scholar 

  • Editorial. Acitretin suspended in France. Scrip 1563: 22, 1990

  • Fairley JA, Ewing N, Keng P. Retinoic acid decreases the free intracellular calcium level of keratinocytes. Abstract. Journal of Investigative Dermatology 88: 488, 1987

    Google Scholar 

  • Fiedler-Nagy C, Georgiadis A, Coffey JW. Effects on retinoids on arachidonic acid release and metabolism by rat peritoneal macrophages. Agents and Actions 16: 620–621, 1985

    Google Scholar 

  • Fiedler-Weiss VC, Rumsfield J, Wendrow A, Guild JM, Buys CM, et al. Evaluation of oral acitretin (Ro 10-1670) in the treatment of severe psoriasis. Abstract. Drug Intelligence and Clinical Pharmacy 21: 15A, 1987

    Google Scholar 

  • Fontana JA, Reppucci A, Durham JP, Miranda D. Correlation between the induction of leukemic cell differentiation by various retinoids and modulation of protein kinases. Cancer Research 46: 2468–2473, 1986

    PubMed  CAS  Google Scholar 

  • Geiger J-M, Czarnetzki BM. Acitretin (Ro 10-1670), Etretin: overall evaluation of clinical studies. Dermatologica 176: 182–190, 1988

    PubMed  CAS  Google Scholar 

  • Geiger JM, Ott F, Bollag W. Clinical evaluation of an aromatic retinoid, Ro 10-1670, in severe psoriasis. Current Therapeutic Research 35: 735–740, 1984

    Google Scholar 

  • Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, et al. Acitretin improves psoriasis in a dose-dependent fashion. Journal of the American Academy of Dermatology 18: 655–662, 1988

    PubMed  CAS  Google Scholar 

  • Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. Journal of the American Academy of Dermatology 19: 458–469, 1988

    PubMed  CAS  Google Scholar 

  • Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. Journal of the American Academy of Dermatology 20: 1088–1093, 1989

    PubMed  CAS  Google Scholar 

  • Harper RA. Specificity in the synergism between retinoic acid and EGF on the growth of adult human skin fibroblasts. Experimental Cell Research 178: 254–263, 1988

    PubMed  CAS  Google Scholar 

  • Hirschel-Scholz S, Siegenthaler G, Saurat J-H. Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP). European Journal of Clinical Investigation 19: 220–227, 1989a

    PubMed  CAS  Google Scholar 

  • Hirschel-Scholz S, Siegenthaler G, Saurat J-H. Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP). British Journal of Dermatology 120: 639–644, 1989b

    PubMed  CAS  Google Scholar 

  • Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. Journal of the American Academy of Dermatology 19: 355–356, 1988

    PubMed  CAS  Google Scholar 

  • Hummler H, Schüpbach ME. Studies in reproductive toxicology and mutagenicity with Ro 10-9359. In C.E. Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 49–59, Springer-Verlag, 1981

    Google Scholar 

  • Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. British Journal of Dermatology 120: 665–670, 1989

    PubMed  CAS  Google Scholar 

  • Jensen BK, Milazzo JJ, Lin A. Dose proportionality of acitretin at oral doses ranging from 25 to 100mg in the absence of food. Abstract PP-666. Pharmaceutical Research 4 (Suppl.): S–95, 1987

    Google Scholar 

  • Kádár L, Török L, Geiger J-M. Spermatological investigations in psoriatic patients treated with acetretin. In Reichert U & Shroot B (Eds) Pharmacology of retinoids in the skin. Pharmacology of Skin 3: 253–254, 1989

    Google Scholar 

  • Keddie F. Use of vitamin A in the treatment of cutaneous diseases. Archives of Dermatology and Syphilology 58: 64–73, 1947

    Google Scholar 

  • Kikuchi A, Amagai M, Hayakawa K, Ueda M, Hirohashi S, et al. Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours. British Journal of Dermatology 123: 49–58, 1990

    PubMed  CAS  Google Scholar 

  • Kilcoyne RF. Effects of retinoids in bone. Journal of the American Academy of Dermatology 19: 212–216, 1988

    PubMed  CAS  Google Scholar 

  • Kingston TP, Matt LH, Lowe NJ. Etretin therapy for severe psoriasis. Archives of Dermatology 123: 55–58, 1987

    PubMed  CAS  Google Scholar 

  • Kistler A, Hummler H. Teratogenesis and reproductive safety evaluation of the retinoid etretin (Ro 10-1670). Archives of Toxicology 58: 50–56, 1985

    PubMed  CAS  Google Scholar 

  • Kistler GS, Peter HJ. Antitumor effects of 2 aromatic retinoids (analogues of vitamin A) in human bronchogenic carcinomas grown in vivo (nu/nu-mice) and in vitro. Schweizerische Medizinische Wochenschrift 109: 847–850, 1979

    PubMed  CAS  Google Scholar 

  • Knippel I, Bauer R, Orfanos CE. No influence of three synthetic retinoids (Ro 10-1670, Ro 4-3780, Ro 13-6298) on lipoxygenase activity in two in vitro systems. In W.J. Cunliffe and A.J. Miller (Eds) Retinoid therapy: a review of clinical and laboratory research, pp. 345–347, MTP Press Ltd, Boston, 1984

    Google Scholar 

  • Kochhar DM, Nau H, Penner JD, Hickey T, Dansky L. Developmental toxicity of retinoids and mode of action. Abstract. Teratology 31: 25A–26A, 1985

    Google Scholar 

  • Kochhar DM, Penner JD, Minutella LM. Biotransformation of etretinate and developmental toxicity of etretin and other aromatic retinoids in teratogenesis bioassays. Drug Metabolism and Disposition 17: 618–624, 1989

    PubMed  CAS  Google Scholar 

  • Kragballe K, Jansen CT, Geiger J-M, Bjerke JR, Falk ES, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Dermato-Venereologica 69: 35–40, 1989

    PubMed  CAS  Google Scholar 

  • Larsen FG, Jakobsen P, Eriksen H, Grønhøj J, Kragballe K, et al. The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. Journal of Clinical Pharmacology 31: 477–483, 1991

    PubMed  CAS  Google Scholar 

  • Larsen FG, Jakobsen P, Larsen CG, Kragballe K, Nielsen-Kudsk F. Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. Pharmacology and Toxicology 62: 159–165, 1988

    PubMed  CAS  Google Scholar 

  • Larsen FG, Jakobsen P, Larsen CG, Norgaard A, Kragballe K, et al. Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacology and Toxicology 61: 85–88, 1987

    PubMed  CAS  Google Scholar 

  • Lasnitzki I. Reversal of methylcholanthrene-induced changes in mouse prostates in vitro by retinoic acid and its analogues. British Journal of Cancer 34: 239–248, 1976

    PubMed  CAS  Google Scholar 

  • Lassus A, Geiger J-M. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. British Journal of Dermatology 119: 755–759, 1988

    PubMed  CAS  Google Scholar 

  • Lassus A, Geiger J-M, Nyblom M, Virrankoski T, Kaartamaa M, et al. Treatment of severe psoriasis with etretin (Ro 10-1670). British Journal of Dermatology 117: 333–341, 1987

    PubMed  CAS  Google Scholar 

  • Lauharanta J, Geiger J-M. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. British Journal of Dermatology 121: 107–112, 1989

    PubMed  CAS  Google Scholar 

  • Lauharanta J, Käpyaho K, Kanerva L. Effect of retinoids on the fructolytic activity of human spermatozoa. In Sauret (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva, 1984, pp. 411–414, Karger, Basel, 1985

    Google Scholar 

  • Lauharanta J, Kanerva L, Turjanmaa K, Geiger J-M. Clinical ultrastructural effects of acitretin in Darier’s disease. Acta Dermato-Venereologica 68: 492–498, 1988

    PubMed  CAS  Google Scholar 

  • Laurberg G, Geiger JM, Hjorth N, Holm P, Hon-Jensen K, et al. Treatment of lichen planus with acitretin. Journal of the American Academy of Dermatology 24: 434–437, 1991

    PubMed  CAS  Google Scholar 

  • Ledo A, Martín M, Geiger JM, Marrón JM. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomised double-blind parallel study comparing acitretin and etretinate. International Journal of Dermatology 27: 656–660, 1988

    PubMed  CAS  Google Scholar 

  • Levine L, Ohuchi K. Retinoids as well as tumour promoters enhance deacylation of cellular lipids and prostaglandin production in MDCK cells. Nature 276: 274–275, 1978

    PubMed  CAS  Google Scholar 

  • Löfberg B, Chahoud I, Bochert G, Nau H. Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. Teratology 41: 707–716, 1990

    PubMed  Google Scholar 

  • Lotan R, Dennert G. Stimulatory effects of vitamin A analogs on induction of cell-mediated cytotoxicity in vivo. Cancer Research 39: 55–58, 1979

    PubMed  CAS  Google Scholar 

  • Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, et al. Acitretin plus UVB therapy for psoriasis. Journal of the American Academy of Dermatology 24: 591–594, 1991

    PubMed  CAS  Google Scholar 

  • Madhok R, Muller SA, Dicken CH. Treatment of psoriasis with etretin: a preliminary report. Mayo Clinic Proceedings 62: 1084–1089, 1987

    PubMed  CAS  Google Scholar 

  • Marth Ch, Zech J, Böck G, Mayer I, Daxenbichler G. Effects of retinoids and interferon-gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha. International Journal of Cancer 40: 840–845, 1987

    CAS  Google Scholar 

  • Mascaro JM, Aliaga A, Armijo M, Brufau C, Camacho F, et al. Multicentric study on the efficacy and tolerance of acitretin. Abstract. Dermatologica 181: 353–354, 1990

    Google Scholar 

  • Massarella J, Vane F, Buggé C, Rodriguez L, Cunningham WJ, et al. Etretinate kinetics during chronic dosing in severe psoriasis. Clinical Pharmacology and Therapeutics 37: 439–446, 1985

    PubMed  CAS  Google Scholar 

  • McNamara PJ, Jewell RC. The effect of food on the bioavailability of etretin (Ro 10-1670). Abstract PP-658. Pharmaceutical Research 4 (Suppl.): S–93, 1987

    Google Scholar 

  • McNamara PJ, Jewell RC, Jensen BK, Brindley CJ. Food increases the bioavailability of acitretin. Journal of Clinical Pharmacology 28: 1051–1055, 1988

    PubMed  CAS  Google Scholar 

  • Meffert H, Sönnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate. Acta Dermato-Venereologica 146 (Suppl.): 176–177, 1989

    PubMed  CAS  Google Scholar 

  • Meigel W. Acitretin and PUVA or UVB. Abstract. Dermatologica 181: 354, 1990

    Google Scholar 

  • Melnick B, Glück S, Jungblut RM, Goerz G. Retrospective radiographic study of skeletal changes after long-term etretinate therapy. British Journal of Dermatology 116: 207–212, 1987

    Google Scholar 

  • Mørk NJ, Kolbenstvedt A, Austad J. Efficacy and skeletal side effects of longterm acitretin treatment: first year results of a prospective investigation. Abstract. Dermatologica 181: 360, 1990

    Google Scholar 

  • Mueller KP, Godt C, Detmar M, Stadler R, Orfanos CE. Effect of aromatic retinoids on human skin fibroblasts in vitro. Abstract. Journal of Investigative Dermatology 90: 249, 1988

    Google Scholar 

  • Nakajima M, Lotan D, Baig MM, Carralero RM, Wood WR, et al. Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat-mammary adenocarcinoma cells. Cancer Research 49: 1698–1706, 1989

    PubMed  CAS  Google Scholar 

  • Nanney LB, Stoscheck CM, Magid M, King Jr LE. Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. Journal of Investigative Dermatology 86: 260–265, 1986

    PubMed  CAS  Google Scholar 

  • Nazzaro V, Blanchet-Bardon C, Mimoz C, Revuz J, Puissant A. Papillon-Lefévre syndrome. Archives of Dermatology 124: 533–539, 1988

    PubMed  CAS  Google Scholar 

  • Olsen EA, Weed WW, Meyer CJ, Cobo LM. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. Journal of the American Academy of Dermatology 21: 681–686, 1989

    PubMed  CAS  Google Scholar 

  • Paravicini U, Stöckel K, MacNamara PJ, Hänni R, Busslinger A. On metabolism and pharmacokinetics of an aromatic retinoid. Annals — New York Academy of Sciences 359: 54–67, 1981

    CAS  Google Scholar 

  • Paravicini U, Camenzind M, Gower M, Geiger J-M, Saurat J-H. Multiple-dose pharmacokinetics of Ro 10-1670, the main metabolite of Tigason. Abstract 46. Dermatologica 169: 240, 1984

    Google Scholar 

  • Paravicini U, Camenzind M, Gower M, Geiger J-M, Saurat JH. Multiple dose pharmacokinetics of Ro 10-1670, the main metabolite of etretinate (Tigason®). In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva, 1984, pp. 289–292, Karger, Basel, 1985

    Google Scholar 

  • Parsch E-M, Ruzicka Th, Przybilla B, Schill W-B. Andrological investigations in men treated with acitretin (Ro 10-1670). Andrologia 22: 479–482, 1990

    PubMed  CAS  Google Scholar 

  • Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330: 444–450, 1987

    PubMed  CAS  Google Scholar 

  • Pitts JD, Hamilton AE, Kam E, Burk RR, Murphy JP. Retinoic acid inhibits junctional communication between animal cells. Carcinogenesis 7: 1003–1010, 1986

    PubMed  CAS  Google Scholar 

  • Pittsley RA, Yoder FW. Skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. New England Journal of Medicine 308: 1012–1014, 1983

    PubMed  CAS  Google Scholar 

  • Pohl J, Christophers E. Mitogenic properties of aromatic retinoids: in vivo and in vitro effects of epidermal cells. In C.E. Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 133–138, Springer-Verlag, 1981

    Google Scholar 

  • Ponec M, Boonstra J. Effects of retinoids and hydrocortisone on keratinocyte differentiation, epidermal growth factor binding and lipid metabolism. Dermatologica 175 (Suppl. 1): 67–72, 1987

    PubMed  CAS  Google Scholar 

  • Ponec M, Kempenaar J, Weeheim A. Effect of EGF and retinoids on the proliferation of squamous carcinoma cells. Abstract 130. Journal of Investigative Dermatology 89: 131, 1987

    Google Scholar 

  • Priestley GC. Proliferation and glycosaminoglycans secretion in fibroblasts from psoriatic skin: differential responses to retinoids. British Journal of Dermatology 117: 575–583, 1987

    PubMed  CAS  Google Scholar 

  • Raynaud F, Leduc C, Anderson WB, Evain-Brion D. Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity. Journal of Investigative Dermatology 89: 105–110, 1987

    PubMed  CAS  Google Scholar 

  • Rollman O, Vahlquist A. Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate. British Journal of Dermatology 109: 439–447, 1983

    PubMed  CAS  Google Scholar 

  • Ruzicka T. Effect of retinoids on arachidonic acid metabolism in human epidermis and polymorphonuclear leukocytes. In Saurat (Ed.) Retinoids: new trends in research and therapy. Retinoid Symposium, Geneva, 1984, pp. 180–182, Karger, Basel, 1985

    Google Scholar 

  • Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Archives of Dermatology 124: 897–902, 1988

    PubMed  CAS  Google Scholar 

  • Ruzicka T, Sommerburg C, Braun-Falco O, Köster W, Lengen W, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Archives of Dermatology 126: 482–486, 1990

    PubMed  CAS  Google Scholar 

  • Saurat J-H, Hirschel-Scholz S, Salomon D, Siegenthaler G. Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link. Dermatologica 175 (Suppl. 1): 13–19, 1987

    PubMed  Google Scholar 

  • Saurat J-H, Geiger J-M, Amblard P, Beani J-C, Boulanger A, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177: 218–224, 1988

    PubMed  CAS  Google Scholar 

  • Schmitt A, Hauser C, Didierjean L, Merot Y, Dayer J-M, et al. Systemic administration of etretin increases epidermal interleukin I in the rat. British Journal of Dermatology 116: 615–622, 1987

    PubMed  CAS  Google Scholar 

  • Schröder K, Zaun H, Holzmann H, Altmeyer P, El-Gammal S. Pustulosis palmo-plantaris, clinical and histological changes during etretin (acitretin) therapy. Acta Dermato-Venereologica 146 (Suppl.): 111–116, 1989

    PubMed  Google Scholar 

  • Siegenthaler G, Saurat J-H. Therapy with a synthetic retinoid — (Ro 10-1670) etretin — increases the cellular retinoic acid-binding protein in nonlesional psoriatic skin. Journal of Investigative Dermatology 87: 122–124, 1986

    PubMed  CAS  Google Scholar 

  • Siegenthaler G, Saurat J-H. Retinoid binding proteins and human skin. Pharmacology and Therapeutics 40: 45–54, 1989

    PubMed  CAS  Google Scholar 

  • Siegenthaler G, Saurat J-H, Hotz R, Camenzind M, Merot Y. Cellular retinoic acid-but not cellular retinol-binding protein is elevated in psoriatic plaques. Journal of Investigative Dermatology 86: 42–45, 1986a

    PubMed  CAS  Google Scholar 

  • Siegenthaler G, Saurat J-H, Salomon D, Mérot Y. Skin cellular retinoid-binding proteins and retinoid-responsive dermatoses. Dermatologica 173: 163–173, 1986b

    PubMed  CAS  Google Scholar 

  • Sigg C, Bruckner-Tuderman L, Gilardi S, et al. Andrological investigations in patients treated with etretin. Dermatologica 175: 48–49, 1987

    PubMed  CAS  Google Scholar 

  • Stadler R, Müller R, Detmar M, Orfanos CE. Retinoids and keratinocyte differentiation in vitro. Dermatologica 175 (Suppl. 1): 45–55, 1987

    PubMed  CAS  Google Scholar 

  • Steele CE, Marlow R, Turton J, Hicks RM. In-vitro teratogenicity of retinoids. British Journal of Experimental Pathology 68: 215–223, 1987

    PubMed  CAS  Google Scholar 

  • Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. New England Journal of Medicine 310: 1156–1161, 1984

    PubMed  CAS  Google Scholar 

  • Stern RS, Parrish JA, Fitzpatrick TB, Bleich HL. Actinic degeneration in association with long-term use of PUVA. Journal of Investigative Dermatology 84: 135–138, 1985

    PubMed  CAS  Google Scholar 

  • Stevens VJ, Kwasniewski BA. Retinoids stimulate endothelial cell proliferation in vitro. Abstract. Journal of Investigative Dermatology 90: 610, 1988

    Google Scholar 

  • Stuck AE, Brindley CJ, Busslinger A, Frey FJ. Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis. British Journal of Clinical Pharmacology 27: 301–304, 1989

    PubMed  CAS  Google Scholar 

  • Takase S, Ong DE, Chytil F. Transfer of retinoic acid from its complex with cellular retinoic acid-binding protein to the nucleus. Archives of Biochemistry and Biophysics 247: 328–334, 1986

    PubMed  CAS  Google Scholar 

  • Takematsu H, Suzuki R, Tagami H, Kumagai K. Interleukin-1-like activity in horny layer extracts: decreased activity in scale extracts of psoriasis and sterile pustular dermatoses. Dermatologica 172: 236–240, 1986

    PubMed  CAS  Google Scholar 

  • Tanew A, Guggenbichler A, Hönigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. Journal of the American Academy of Dermatology 25: 682–684, 1991

    PubMed  CAS  Google Scholar 

  • Tong PS, Mayes DM, Wheeler LA. Differential effects of retinoids on DNA synthesis in calcium-regulated murine epidermal keratinocyte cultures. Journal of Investigative Dermatology 90: 861–868, 1988

    PubMed  CAS  Google Scholar 

  • Török L, Kádár L, Geiger J-M. Acitretin treatment of severe psoriasis. Acta Dermato-Venereologica 146 (Suppl.): 104–106, 1989

    PubMed  Google Scholar 

  • Trown PW, Buck MJ, Hansen R. Inhibition of growth and regression of a transplantable rat chondrosarcoma by three retinoids. Cancer Treatment Reports 60: 1647–1653, 1976

    PubMed  CAS  Google Scholar 

  • Tsambaos D, Orfanos CE. Ultrastructural evidence suggesting an immunomodulatory activity of oral retinoid. British Journal of Dermatology 104: 37–45, 1981

    PubMed  CAS  Google Scholar 

  • Tsambaos D, Zimmermann B, Orfanos CE. Effects of retinoids on chondrogenesis and epidermogenesis in vitro. In W.J. Cunliffe, A.J. Miller (Eds) Retinoid therapy: a review of clinical and laboratory research, pp. 119–133, MTP Press Ltd, Boston, 1984

    Google Scholar 

  • Väätäinen N, Hollmen A, Fräki JE. Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis. Journal of the American Academy of Dermatology 12: 52–55, 1985

    PubMed  Google Scholar 

  • Vahlquist A, Rollman O. Clinical pharmacology of 3 generations of retinoids. Dermatologica 175 (Suppl. 1): 20–27, 1987

    PubMed  Google Scholar 

  • Vahlquist A, Michaëlsson G, Kober A, Sjöholm I, Palmskog G, et al. Retinoid-binding proteins and the plasma transport of etretinate (Ro 10-9359) in man. In C.E. Orfanos et al. (Eds) Retinoids: advances in basic research and therapy, pp. 109–116, Springer-Verlag, 1981

    Google Scholar 

  • Vahlquist A, Rollman O, Pihl-Lundin I. Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fat. Acta Dermato-Venereologica 66: 431–434, 1986

    PubMed  CAS  Google Scholar 

  • Vahlquist C, Selinus I, Vessby B. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Dermato-Venereologica 68: 300–305, 1988

    PubMed  CAS  Google Scholar 

  • van de Kerkhof PCM, Chang A, van Dooren-Greebe R, Geiger JM, Happle R. Intra-epidermal accumulation of polymorphonuclear leukocytes in persistent palmoplantar pustulosis during treatment with acitretin. Acta Dermato-Venereologica 68: 499–503, 1988

    PubMed  Google Scholar 

  • van Dooren-Greebe RJ, van de Kerkhof PCM, Happle R. Acitretin monotherapy in Darier’s disease. British Journal of Dermatology 121: 375–379, 1989

    PubMed  Google Scholar 

  • Vane FM, Buggé CJL, Rodriguez LC. Identification of etretinate metabolites in human blood. Drug Metabolism and Disposition 17: 280–285, 1989

    PubMed  CAS  Google Scholar 

  • Verma AK, Rice HM, Shapas BG, Boutwell RK. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis by vitamin A analogs (retinoids). Cancer Research 38: 793–801, 1978

    PubMed  CAS  Google Scholar 

  • Viglioglia PA, Villanueva CR, Martorano AD, Cahuepé AM, Traballi CA. Efficacy of acitretin in severe cutaneous lichen planus. Journal of the American Academy of Dermatology 22: 852–853, 1990

    PubMed  CAS  Google Scholar 

  • Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 28: 6–37, 1984

    PubMed  CAS  Google Scholar 

  • Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs 26: 9–43, 1983

    PubMed  CAS  Google Scholar 

  • Wetherall NT, Taylor CM. The effects of retinoid treatment and antiestrogens on the growth of T47D human breast cancer cells. European Journal of Cancer and Clinical Oncology 22: 53–59, 1986

    CAS  Google Scholar 

  • Wolff K. Side-effects of psoralen photochemotherapy. British Journal of Dermatology 122 (Suppl. 36): 117–125, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Tania Pilkington & Rex N. Brogden

Authors
  1. Tania Pilkington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rex N. Brogden
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: L. Dubertret, Clinique des Maladies Cutanees, Hôpital St-Louis, Université Paris, Paris, France; A.M. Kligman, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; H.I. Mai bach, Department of Dermatology, University Hospital, San Francisco, California, USA; E.A. Olsen, Department of Medicine, Dermatology Division, Duke University Medical Center, Durham, North Carolina, USA; R.G. Park, Health Care Centre, Waikanae, New Zealand; G. Siegenthaler, Clinique et Policlinique de Dermatologie de Vénéréologic Hôpital Cantonal Universitaire de Genève, Genève, Switzerland; H. Takematsu, Department of Dermatology, Tohoku University School of Medicine, Seiryo-Machi, Sendai, Japan; L. Török, Department of Dermatology, County Hospital, Kecskamet, Hungary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pilkington, T., Brogden, R.N. Acitretin. Drugs 43, 597–627 (1992). https://doi.org/10.2165/00003495-199243040-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199243040-00010

Keywords

Search

Navigation